Abstract
HCC is one of the most common cancers world-wide. The prognosis of untreated patients is universally dismal.1 Surgical resection is the treatment of choice and offers the only chance of prolonged survival.2 Yet our best surgical attempts are often frustrated by advanced disease and coexistent cirrhosis that renders the patient non-resectable. The results of orthotopic liver transplantation (OLT) in patients with advanced HCC have been poor. Likewise, chemotherapy and other non operative strategies have failed to prolong survival. With improved surgical techniques, resection of multiple tumours in more than one lobe and those with vascular involvement is now feasible and is only recently being explored.3,4 The aim of this study was to assess the result of major liver resection in patients with advanced (Stage IV) HCC in terms of safety and survival.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Akashi Y, Koreeda C, Enomoto S, et al. Prognosis of unresectable hepatocellular carcinoma: and evaluation based on multivariate analysis of 90 cases. Hepatology 1991; 14(2): 262–8.
Ringe B, Pichlmayr R, Wittekind C and Tusch G. Surgical Treatment of Hepatocellular Carcinoma: Experience with Liver Resection and Transplantation in 198 Patients. World J Surg 1991; 15: 270–85.
Yamamoto M, Iizuka H, Matsuda M, et al. The indications for tumor mass reduction surgery and subsequent multidisciplinary treatment in stage IV hepatocellular carcinoma. Surg Today 1993; 23: 675–81.
Tanaka A, Morimoto T, Ozaki N, et al. Extension of surgical indication for advanced hepatocellular carcinoma: Is it possible to prolong life span or improve quality of life? Hepato-Gastroenterology 1996; 43: 1172–81.
Hermanek P and S. LH. Liver; TNM classification of malignant tumours. 1992. Springer Verlag. Berlin.
Habib N, Zografos G, Dalla Serra G, Greco L and Bean A. Liver resection with total vascular exclusion for malignant tumours. B J Surg 1994; 81: 1181–4.
Huguet C and Gavelli A. Total vascular exclusion for liver resection. HepatoGastroenterology 1998; 45: 368–9.
Shimamura Y, Gunvèn P, Ishii M, Ono M and Abe K. Debulking surgery and arterial embolization for unresectable liver cancer. Hepato-Gastroenterology 1993; 40: 10–3.
Penn I. Hepatic transplantation for primary and metastatic cancer of the liver. Surgery 1991; 110(4): 726–34.
McPeake JR, O’Grady JG, Zaman S, et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 1993; 18: 226–34.
Ozawa K, Takayasu T, Kumada K, et al. Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period. Am J Surg 1991; 161: 677–81.
Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56(4): 918–28.
Lotze MT, Flickinger JC and Carr BI. Hepatobiliary neoplasms, in Cancer principles and practice of oncology (De Vita VT, Hellman S and Rosenberg SA) 4th ed. 1993. J. B. Lippincott, Philadelphia, pp. 883–914
Venook AP. Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 1994; 12(6): 1323–34.
Lim RS and Bongard FS. Hepatocellular carcinoma: changing concepts in diagnosis and management. Arch Surg 1984; 1 19: 637–641.
Tanikawa K and Tanaka M. Treatment of advanced hepatocellular carcinoma. Intern Med 1995; 34(4): 300–2.
Kanematsu T, Matsumata T, Furuta T, et al. Lipiodol drug targetting in the treatment of primary hepatocellular carcinoma. Hepato-Gastroenterology 1990; 37(5): 442–4.
Stuart K, Stokes K, Jenkins R, Trey C and Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993; 72(11): 3202–9.
Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992; 69(4): 925–9.
Wu CC, Ho WL, Yeh DC, Liu TJ and P’eng FK. Hepatic resection for bilobar multicentric hepatocellular carcinoma - is it justified(abstract)? Hepato-Gastroenterology 1998; 45(Supl. II): LXXXV.
Kim Hi, Song IS, Lim MK, Shon DH and Kwun KB. Indication and limitation of hepatectomy in advanced hepatocellular carcinoma(abstract). Hepato-Gastroenterology 1998; 45(Supl. II): LXXXII.
Regimbeau JM, Farges O, Shen BY, et al. Is surgery justified for large hepatocellular carcinoma(abstract)? Hepato-Gastroenterology 1998; 45(Supl. II): LXXI.
Ikai I, Yamaoka Y, Yamamoto Y, et al. Surgical intervention for patients with stage IVA hepatocellular carcinoma without lymph node metastasis. Ann Surg 1998; 227(3): 4339.
Shimada M, Takenaka K, Kawahara N, et al. Surgical treatment strategy for patients with stage IV hepatocellular carcinoma. Surgery 1996; 119: 517–22.
Yamaoka Y, Kumada K, Ino K, et al. Liver resection for hepatocellular carcinoma with direct removal of tumor thrombi in the main portal vein. World J Surg 1992; 16(6): 11726.
Kumada K, Ozawa K, Okamoto R, et al. Hepatic resection for advanced hepatocellualr carcinoma with removal of portal vein tumor thrombi. Surgery 1990; 108(5): 821–7.
Ohwada S, Tanahashi Y, Kawashima Y, et al. Surgery for tumour thrombi in the right atrium and inferior vena cava of patients with recurrent hepatocellular carcinoma. HepatoGastroenterology 1994; 41(2): 154–7.
Konishi M, Ryu M, Kinoshita T and Inoue K. Surgical treatment for hepatocellular carcinoma with direct removal of tumor thrombus in the main portal vein(abstract). Hepato-Gastroenterology 1998; 45(Supl. II): LXXXI.
Tanaka A, Morimoto T and Yamaoka Y. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepato-Gastroenterology 1996; 43: 637–43.
Yamamoto K, Takenaka K, Kawahara N, et al. Indications for palliative reduction surgery in advanced hepatocellular carcinoma. The use of a remnant tumour index. Arch Surg 1997; 132(120–3):
Ding SF, Habib NA, Dooley J, et al. Loss of constitutional heterozygosity on chromosome 5q in HCC without cirrhosis. Br J Cancer 1991; 64: 1083–87.
Murakami Y, Hayashi K, Hirohashi S and Sekiya T. Aberrations of the tumour suppressor p53 and retinoblastoma genes in human hepatocellular carcinoma. Cancer Res 1991; 51(20): 5520–5.
Chiu JH, Kao HL, Wu LH, Chang HM and Lui WY. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J Clin Inves 1992; 89(2): 539–45.
Nagorney DM, Adson MA, Weiland LH, Knigh tCDJ and Smalley SR. Fibrolamellar hepatoma. Am J Surg 1985; 149: 113–9.
Ringe B, Wittekind C, Weimann A, Tusch G and Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynae Obst 1992; 175(4): 299–305.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Usatoff, V., Isla, A.M., Habib, N.A. (2002). Liver Resection in Advanced Hepatocellular Carcinoma. In: Habib, N.A. (eds) Multi-Treatment Modalities of Liver Tumours. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0547-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0547-1_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5126-9
Online ISBN: 978-1-4615-0547-1
eBook Packages: Springer Book Archive